A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2015
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hypercholesterolaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 07 Jun 2017 Biomarkers information updated
- 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2015 Esperion Therapeutics expects to hold an end-of-phase II meeting with the US FDA for bempedoic acid in the first half of August 2015, according to a media release.